OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Cystic Fibrosis is 38. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
P402 Separation anxiety or a Kaftrio side effect? Implementation of cognitive behavioural therapy strategies with a young child with cystic fibrosis (CF): A clinical case study	307
P408 The halo effect in cystic fibrosis: when educated patients in turn educate their family carers	136
EPS10.07 Exacerbation characteristics and clinical outcomes in the elexacaftor/tezacaftor/ivacaftor era: same-same but different?	115
WS08.03 How does elexacaftor/tezacaftor/ivacaftor affect improvement in exercise capacity and body composition in adults with cystic fibrosis who have completed an exercise intervention?	103
P131 Effect of deprescribing from inhaled corticosteroids in people with cystic fibrosis: challenges & opportunities for a target trial emulation using the UK CF Registry	102
P296 Characteristics of carbohydrate metabolism disorders in children with cystic fibrosis in the Moscow region	101
P109 Safety of elexacaftor/tezacaftor/ivacaftor in patients 6 through 18 years with cystic fibrosis and at least one F508del allele: a retrospective Italian multicenter study	88
WS13.03 Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del	85
EPS10.06 Highly-effective CFTR modulation is associated with greater height and peak lung function in children with cystic fibrosis	79
EPS8.02 Evolving physiotherapy airway clearance technique (ACT) interventions during cystic fibrosis (CF) pregnancy in the variant specific therapy (VST) era	74
P172 Oscillometry: assessment of bronchial obstruction in children with cystic fibrosis	72
P078 Hyperacute response to cystic fibrosis transmembrane conductance regulator modulation	68
P227 Life threatening infection with a highly resistant Achromobacter xylosoxidans strain	65
P024 Analysis of the effect of cytochrome P450 genes polymorphism on the efficacy and safety of CFTR modulator therapy in cystic fibrosis	63
Autoimmunity in people with cystic fibrosis	61
P478 Multiple breath inert gas wash out in infants and toddlers with cystic fibrosis before and after initiating inhaled hypertonic saline	61
“Mind the gap”- will we ever see equal median predicted survival for males and females in cystic fibrosis?	59
Contents	59
564 “How do you live the best life you can with this pain?” A qualitative study of the challenges of living with CF and pain in the modulator era	58
WS15.05 Improvements in structural lung disease in people with CF aged 12 and above on elexacaftor/tezacaftor/ivacaftor are sustained for up to two years	58
209 Inositol-requiring enzyme 1β is a therapeutic target for cystic fibrosis airway muco-obstructive disease	54
235 Differential regulation of immune function by highly effective CFTR modulators in THP-1-derived macrophages	53
184 Bioengineered three-dimensional cystic fibrosis lung airway model for drug testing	52
679 Effect of hybrid closed loop insulin delivery on glycemic control in adolescents and adults with cystic fibrosis-related diabetes	49
808 Implementation of physical therapy and exercise education in annual cystic fibrosis clinic	48

260 RCT2100 rescue of cystic fibrosis (CF) transmembrane conductance regulator function in CF human bronchial epithelial cells and mucociliary clearance in CF ferrets	46
39 Using mouse models to understand the critical roles of granulocyte macrophage colony stimulating factor and macrophages for control of pulmonary Mycobacterium abscessus infection	45
365 Differential effects of (S)- and (R)-vanzacaftor on BKCa potentiation and CFTR correction	44
99 Development and validation of a deep neural network to predict antimicrobial resistance in people with cystic fibrosis using routinely collected electronic healthcare record data	43
27 Standing up to the “bully”: Staphylococcus aureus can sustain long-term infection in the presence of Pseudomonas aeruginosa and may outcompete in the cystic fibrosis airway	43
490 What are the experiences of cystic fibrosis clinical nurse specialists? Are systemic practice ideas unknowingly incorporated when working with children and families?	42
304 Assessing a novel dual-endonuclease system in restoring CFTR expression in cystic fibrosis humanized mouse and human airway models	41
320 Gain-of-function CFTR mutation improves function of W1282X CFTR	41
558 Challenges faced by parents of children with cystic fibrosis in Ireland: The Irish Comparative Outcome Study of Cystic Fibrosis	40
529 Are adults with cystic fibrosis choosing to continue with airway clearance therapy in the era of highly effective gene modulator therapy?	40
526 Non-surgical management of urinary incontinence in women with cystic fibrosis	40
644 Timely initiation of pancreatic enzyme replacement therapy for surgical cystic fibrosis infants in the neonatal intensive care unit	39
586 Description of a novel therapeutic support group for siblings of children with cystic fibrosis: Siblings Supporting Others and Achieving Resilience	38